Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Memory Pharmaceuticals has initiated a phase IIa clinical trial of MEM1003 in patients with mild to moderate Alzheimer's disease.
Subscribe to our email newsletter
Under the terms of the company’s license agreement with Bayer AG, the company is obligated to make a $1 million milestone payment to Bayer as a result of the commencement of this phase IIa clinical trial for MEM1003.
The trial is a multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of two dose levels of MEM1003 in approximately 180 patients with mild to moderate Alzheimer’s disease at approximately 50 centers.
The primary outcome measure of the trial is a twelve-week change in the Alzheimer’s disease “assessment scale”. Secondary measures will assess changes in activities of daily living, behavior and global function.
“It is believed that one of the hallmarks of Alzheimer’s disease is an impaired regulation of calcium within the central nervous system,” said Dr David Lowe, chief scientific offer. “As a calcium channel modulator, MEM1003 has the potential to re-establish normal cellular functioning, thereby enhancing cognition in Alzheimer’s patients and reducing the progression of this debilitating disease.”